Here we found that ONC213 sensitizes venetoclax + azacitidine-resistant cells to venetoclax, similar to inherently venetoclax-resistant AML cell lines (THP-1 and OCI-AML3). The gene discussed is RUNX2; the disease is acute myeloid leukemia.